FDA: MS Drug Tysabri is Riskiest in Third Year of Treatment
Biogen Idec’s multiple sclerosis drug Tysabri poses the highest risk of brain infection during the third year of treatment, U.S. health officials warned on April 22. An infection called progressive multiform leukoencephalopathy (PML), occurs in an estimated 1.5 per 1,000 patients treated with Tysabri during months 25 to 36, the Food and Drug Administration said. The FDA reported that the PML risk was 0.3 per 1,000 patients during the first two years of treatment. After three years, the rate was …
Continue →Four More Brain Infections Found in Tysabri Users, Biogen Says
Four more cases of a rare but potentially fatal brain infection have been found among patients taking the multiple sclerosis drug Tysabri, the drug’s maker said.
Continue →Makers of Tysabri, Raptiva Join Forces to Research Rare Brain Infections
Three drug makers are forming a consortium solely dedicated to researching cases of a rare but potentially deadly brain infection linked to users of their immunosuppressive medications.
Continue →Europe Looking Again at Tysabri for Link to Fatal Brain Infection
The multiple sclerosis and Crohn’s disease drug Tysabri is going back under the microscope in Europe for a possible link to cases of a rare but potentially deadly brain infection called progressive multifocal leukoencephalopathy (PML), according to various news reports.
Continue →Multiple Sclerosis and Crohn’s Disease Drug Tysabri Linked to Rare, Deadly Brain Infection
Tysabri, a drug prescribed to tens of thousands of multiple sclerosis patients and also used to a lesser extent to treat the form of inflammatory bowel disease called Crohn’s disease, has been linked to more than a dozen cases of a potentially deadly opportunistic infection of the brain.
Continue →
facebook
rss
twitter